Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
Receptos doses first patient in Phase 2 trial for RPC1063 in ulcerative colitis
Phase III study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis (TOPIC)
Mechanism-based CNS Disease Modeling: Applications in Neurology and Psychiatry Drug Research & Development
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.
Safety Study of Interferon Beta-1a for Acute Stroke
Pericytes are required for blood-brain barrier integrity during embryogenesis.
FDA approval announcement for ofatumumab
Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis
Glatiramer acetate, an anti-demyelination drug, reduced rats' epileptic seizures induced by pentylenetetrazol via protection of myelin sheath.
Normal Appearing and Diffusely Abnormal White Matter in Patients with Multiple Sclerosis Assessed with Quantitative MR.
Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate.
LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma.
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
New insights into signaling during myelination in zebrafish.

Pages